Narrative Update • May 04
Have your own idea? Try our Stock Screener
French (CAC) Biotech Industry Analysis
UpdatedMay 09, 2026
DataAggregated Company Financials
Companies22
- 7D6.8%
- 3M3.2%
- 1Y308.7%
- YTD-8.6%
The Biotech industry is up 6.8% in the last week, with ABIVAX Société Anonyme up 9.4%. During this same period, the DBV Technologies underperformed, falling 6.2%. This means that the industry has gained 309% over the past year. Looking forward, earnings are forecast to grow by 57% annually.
Industry Valuation and Performance
Has the French Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 09 May 2026 | €11.3b | €517.9m | -€834,456,128.57 | 16.5x | -13.5x | 21.8x |
| Mon, 06 Apr 2026 | €12.6b | €581.0m | -€884,955,295.30 | 13.4x | -14.2x | 21.7x |
| Wed, 04 Mar 2026 | €10.9b | €560.7m | -€765,487,849.92 | 12.8x | -14.2x | 19.4x |
| Fri, 30 Jan 2026 | €10.8b | €558.7m | -€761,675,161.93 | 13.7x | -14.2x | 19.4x |
| Sun, 28 Dec 2025 | €12.2b | €641.3m | -€693,469,032.33 | 10.1x | -17.5x | 19x |
| Tue, 25 Nov 2025 | €2.5b | €637.6m | -€432,182,673.39 | 10.6x | -5.9x | 4x |
| Thu, 23 Oct 2025 | €2.5b | €645.3m | -€430,189,656.78 | 10.1x | -5.8x | 3.9x |
| Sat, 20 Sep 2025 | €2.5b | €672.6m | -€448,469,552.72 | 14.4x | -5.6x | 3.7x |
| Mon, 18 Aug 2025 | €2.6b | €673.9m | -€445,361,747.38 | 15.4x | -5.8x | 3.8x |
| Wed, 16 Jul 2025 | €2.0b | €656.3m | -€453,649,323.86 | 16.3x | -4.4x | 3x |
| Fri, 13 Jun 2025 | €2.0b | €666.8m | -€495,681,483.46 | 17.4x | -4.1x | 3.1x |
| Sun, 11 May 2025 | €2.5b | €667.9m | -€663,601,560.31 | 39.5x | -3.7x | 3.7x |
| Tue, 08 Apr 2025 | €2.1b | €652.7m | -€554,530,579.31 | 13x | -3.7x | 3.2x |
| Thu, 06 Mar 2025 | €2.4b | €648.4m | -€520,309,675.67 | 16.2x | -4.7x | 3.7x |
| Sat, 01 Feb 2025 | €2.4b | €650.1m | -€526,632,992.52 | 16.7x | -4.6x | 3.7x |
| Mon, 30 Dec 2024 | €2.3b | €650.1m | -€526,531,701.82 | 17.4x | -4.4x | 3.6x |
| Wed, 27 Nov 2024 | €2.4b | €654.3m | -€548,494,249.98 | 17.7x | -4.4x | 3.7x |
| Fri, 25 Oct 2024 | €2.8b | €627.7m | -€519,179,326.17 | 18.6x | -5.4x | 4.4x |
| Sun, 22 Sep 2024 | €2.9b | €543.7m | -€590,214,401.80 | 22.5x | -5x | 5.4x |
| Tue, 20 Aug 2024 | €3.1b | €520.3m | -€579,709,875.05 | 37.2x | -5.4x | 6x |
| Thu, 18 Jul 2024 | €3.0b | €511.6m | -€565,692,574.58 | 29.8x | -5.3x | 5.9x |
| Sat, 15 Jun 2024 | €3.0b | €514.4m | -€569,576,604.39 | 26.4x | -5.2x | 5.8x |
| Mon, 13 May 2024 | €3.2b | €502.5m | -€593,891,697.18 | 27.7x | -5.4x | 6.4x |
| Wed, 10 Apr 2024 | €3.3b | €516.1m | -€623,252,845.77 | 22.4x | -5.2x | 6.3x |
| Fri, 08 Mar 2024 | €3.1b | €558.5m | -€672,379,903.07 | 21.9x | -4.6x | 5.6x |
| Sun, 04 Feb 2024 | €3.1b | €594.7m | -€685,665,134.00 | 22.2x | -4.5x | 5.2x |
| Tue, 02 Jan 2024 | €3.2b | €594.0m | -€681,719,515.00 | 23.4x | -4.7x | 5.4x |
| Thu, 30 Nov 2023 | €3.2b | €594.2m | -€682,787,538.00 | 22.4x | -4.6x | 5.3x |
| Sat, 28 Oct 2023 | €3.2b | €804.1m | -€567,175,295.00 | 21.2x | -5.7x | 4x |
| Mon, 25 Sep 2023 | €3.7b | €866.8m | -€616,090,262.00 | 25.9x | -6x | 4.3x |
| Wed, 23 Aug 2023 | €3.7b | €818.3m | -€726,818,352.00 | 24.4x | -5.1x | 4.5x |
| Fri, 21 Jul 2023 | €3.7b | €817.1m | -€733,197,324.00 | 24.9x | -5.1x | 4.6x |
| Sun, 18 Jun 2023 | €3.9b | €820.3m | -€741,652,850.00 | 25.5x | -5.2x | 4.7x |
| Tue, 16 May 2023 | €3.9b | €831.4m | -€760,619,098.00 | 25.9x | -5.1x | 4.7x |
Price to Earnings Ratio
-5.1x
Current Industry PE
- Investors are optimistic on the French Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.5x is lower than the industry's current PS ratio of 21.8x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 15% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the French Healthcare industry?
| FR Market | 0.50% | |
| Healthcare | -4.45% | |
| Biotech | 6.77% | |
| Biotech | 6.77% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | €105.50 | 9.4% +€716.6m | 1,609.9% | PS1828x | |
| NANO Nanobiotix | €36.90 | 28.5% +€396.7m | 1,096.1% | PS54.9x | |
| IVA Inventiva | €4.55 | 5.6% +€49.8m | 42.2% | PS139.8x | |
| GNFT Genfit | €8.52 | 5.4% +€21.9m | 118.1% | PS6.5x | |
| VLA Valneva | €2.40 | 3.8% +€16.7m | -15.2% | PS2.6x |
